AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04904406 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir / Lamivudine Oral Tablet
Description: Discontinuing abacavir by switching from three-drug regimen with dolutegravir/abacavir/lamivudine to two-drug regimen with dolutegravir/lamivudine
Study NCT04145921 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ERAS for MIS-THA
Description: enhanced recovery after surgery (ERAS) pathway for minimally-invasive surgery of total hip arthroplasty (MIS-THA)
Study NCT04145921 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional MIS-THA
Description: conventional pathway for minimally-invasive surgery of total hip arthroplasty (MIS-THA)
Study NCT02534025 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ischemia preconditioining
Description: Elavate blood pressure cuff pressure to 200
Study NCT01812213 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]NAV4694
Study NCT02437422 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SANGUINATE
Description: Single two-hour infusion of SANGUINATE
Study NCT03769870 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Teneligliptin 20mg/day
Description: cross-over
Study NCT03769870 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Atorvastatin 40mg/Day
Description: cross-over
Study NCT01384552 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Package Unit Size - Single Serving
Description: Participants will receive a box of twenty-two, 0.9-oz. packages of pretzels. Participants will receive the box of pretzels in the lab on a Thursday or Friday and will take the box of pretzels home for a period of four days. Participants will bring back the box of pretzels to the lab on the following Monday or Tuesday (depending on the day of the initial receipt of pretzels).
Study NCT01384552 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Package Unit Size - Standard
Description: Participants will receive a box of two, 10-oz. packages of pretzels. Participants will receive the box of pretzels in the lab on a Thursday or Friday and will take the box of pretzels home for a period of four days. Participants will bring back the box of pretzels to the lab on the following Monday or Tuesday (depending on the day of the initial receipt of pretzels).
Study NCT04010656 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PVR-based self-catheterization
Description: Home self-catheterization based on standard of care
Study NCT03133819 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Q-Sense_QST (TSA II)
Description: QST will perform using the Medoc device (TSA2001/VSA3001) following previous published procedures. The measurement will perform on the thenar eminence of the dominant hand and the lateral distal aspect of the foot dorsum of the same side.
Study NCT03594747 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Administered intravenously as described
Study NCT03594747 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Administered intravenously as described
Study NCT03594747 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Administered intravenously as described
Study NCT03594747 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Administered intravenously as described
Study NCT03594747 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Administered intravenously as described
Study NCT03594747 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Administered intravenously as described
Study NCT01818921 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1.8 mg ZGN-440 for injectable suspension
Description: 1.8 mg beloranib
Study NCT02569476 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanubrutinib
Study NCT01367002 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin/Paclitaxel
Description: Paclitaxel 175 mg/m2 will administered intravenously every 21 days for 6 cycles. Carboplatin AUC 5 will be administered intravenously every 21 days for 6 cycles. 100% of patients will receive Carboplatin/Paclitaxel.
Study NCT01367002 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Paclitaxel 175 mg/m2 will be administered intravenously every 21 days for 6 cycles. Carboplatin AUC 5 will be administered intravenously every 21 days for 6 cycles. On day 1, an 8 mg/kg loading dose of trastuzumab will be administered over a 90 minute period. Beginning on day 21, patients will receive 6mg/kg of trastuzumab, administered intravenously every 21 days and continued indefinitely every 21 days after 6 cycles of cytotoxic therapy are completed and until progression of the disease or prohibitive toxicities occur. 50% of patients will receive Carboplatin/Paclitaxel with the addition of Trastuzumab.
Study NCT03303924 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ETX2514 and sulbactam
Description: Each subject will receive three doses of of ETX2514 1.0 g and sulbactam 1.0 g via intravenous (IV) infusion administered every 6 hours with each drug infused over 3 hours
Study NCT02847156 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Physical assessment
Description: 1 year follow-up in CF infants with clinical, microbiological and therapeutic assessments
Study NCT01385566 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ZOSTAVAX™ (Zoster Vaccine Live) Full Dose Subcutaneous
Description: One 0.65 mL injection subcutaneously on Day 1
Study NCT01385566 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ZOSTAVAX™ (Zoster Vaccine Live) 1/3 Dose Subcutaneous
Description: One approximately 0.22 mL injection subcutaneously on Day 1
Study NCT01385566 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ZOSTAVAX™ (Zoster Vaccine Live) Full Dose Intradermal
Description: Two intradermal injections of approximately 0.15 mL each on Day 1
Study NCT01385566 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ZOSTAVAX™ (Zoster Vaccine Live) Partial Doses Intradermal
Description: One intradermal injection of approximately 0.1 mL on Day 1
Study NCT01385566 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Full Dose Intradermal Placebo
Description: Two intradermal placebo injections of approximately 0.15 mL each on Day 1
Study NCT01385566 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intradermal Placebo
Description: One intradermal placebo injection of approximately 0.1 mL on Day 1
Study NCT01385566 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Intradermal Placebo
Description: One intradermal placebo injection of approximately 0.1 mL on Day 1
Study NCT04674930 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise program
Description: Home based exercise program including aerobic and resistance training will be carried out for a period of 6 weeks. Duration of aerobic exercise will be starting at 20 min/session, and progress to 30 ruin/session, with an increased pace according to the patient's capabilities. Resistance training with thera-band for 1 set of 10 repetitions twice a week. One RM will be reassessed weekly, and the program will be adjusted accordingly.
Study NCT01886495 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: nutrition intervention
Study NCT04126460 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: Toripalimab is a type of PD-1 antibody
Study NCT01963962 — intervention group
Intervention type: DRUG
Intervention: Copper IUD
Study NCT01963962 — intervention group
Intervention type: DRUG
Intervention: Levonorgestrel IUD
Study NCT01474889 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RT-CGM
Description: Each device is approximately the size of a pager and transmits with a subcutaneously placed sensor consisting of a 21 - 26 gauge needle 5 - 12 mm in length. Sensors are placed using sterile precautions and changed every 3 - 7 days depending on the manufacturers' instructions. All devices are approved as adjunctive tools to blood glucose monitoring that will be continued at least 4 times daily, before each meal and at bedtime.
Study NCT00976963 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TMP/SMX
Description: Take one twice daily for 3 days for urinary tract infection
Study NCT00976963 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fosfomycin
Description: Mix sachet with 1/2 glass cold water and stir. Drink immediately
Study NCT02257060 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endocardial Ablation
Study NCT02920879 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: PEEP-level, driving pressure
Description: Different levels of PEEP and different levels of driving pressures during mask-ventilation at anesthesia induction.
Study NCT04137055 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZSP0678-10mg
Description: ZSP0678 tablet administered orally under fasted condition
Study NCT04137055 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZSP0678-30mg
Description: ZSP0678 tablets administered orally under fasted condition
Study NCT04137055 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZSP0678-60mg
Description: ZSP0678 tablets administered orally under fasted condition
Study NCT04137055 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZSP0678-120mg
Description: ZSP0678 tablets administered orally under fasted condition
Study NCT04137055 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZSP0678-180mg
Description: ZSP0678 tablets administered orally under fasted condition
Study NCT04137055 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZSP0678-240mg
Description: ZSP0678 tablets administered orally under fasted condition
Study NCT04137055 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZSP0678-320mg
Description: ZSP0678 tablets administered orally under fasted condition
Study NCT04137055 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZSP0678
Description: ZSP0678 tablets administered orally under fasted or fed condition
Study NCT04137055 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZSP0678-Dose 1
Description: ZSP0678 tablets administered orally once daily for 14 Days
Study NCT04137055 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZSP0678-Dose 2
Description: ZSP0678 tablets administered orally once daily for 14 Days
Study NCT02569476 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Study NCT00902915 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide plus dexamethasone
Description: peroral application; lenalidomide dosage according to severity grade of renal failure.
Study NCT02139111 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Oral placebo capsule
Study NCT03769870 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Teneligliptin 20mg/day + Atorvastatin 40mg/day
Description: cross-over
Study NCT03612375 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ENDS (vaporizer/e-cig) and smoking cessation counseling
Description: Participants in the intervention group will receive an ENDS and nicotine-containing e-liquids, which they will be allowed to use ad libitum. Additionally, they will receive smoking cessation counseling. Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 24-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6, 12 and 24 months, participants will be asked to come to a clinical visit.
Study NCT04003051 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Internet-Based Intervention
Description: Use Project Prepare website
Study NCT04003051 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT02139111 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral placebo capsule
Study NCT02139111 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PRC-063 25 mg
Description: Oral 25 mg capsule - active
Study NCT02139111 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PRC-063 45 mg
Description: Oral 45 mg capsule - active
Study NCT02139111 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PRC-063 70 mg
Description: Oral 70 mg capsule - active
Study NCT02139111 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PRC-063 85 mg
Description: Oral 85 mg capsule - active
Study NCT01055171 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propranolol
Description: 40 mg; Single Administration.
Study NCT01055171 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 40 mg; Single Dose.
Study NCT02541682 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: TEMPS-A (Temperament Evaluation of Memphis, Pisa, Paris and San Diego Auto-questionnaire)
Description: Participants filled out the TEMPS-A survey at their first visit.
Study NCT04243967 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music therapy
Description: On the surgery day, the patient is accompanied by music-therapist all the way from her room to the operating theatre in order to monitor and adapt music-therapy intervention.~The patient, prior to the anesthetic, take faces 3 phases of music therapy intervention (1 hour):~* 1° Phase Active Music therapy: the patient takes part in a session of live improvisational music therapy, with the therapist, to elaborate pre-operative stress.~* 2° Phase Relaxation with Receptive Live Music: music therapist play live to relax patients with autogenic training and tunnings breathing.~* 3° Phase playlist listening based on the patient's needs. Patients listen to music with an mp3 player with earphones within the ear canal (H\&H CE mp3/Usb; Headphones on Air in-ear with volume control) with a maximum volume of 60 dB (previously set with a sound level meter).
Study NCT04243967 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Description: Standard perioperative management including perioperative care (without the use of music / music therapy)
Study NCT03478358 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 177Lu-DOTA-EB-TATE 1
Description: The patients were intravenously injected with single dose 0.37GBq-0.74GBq (10-30 mCi) of 177Lu-DOTA-EB-TATE and underwent 68Ga-DOTATATE PET/CT scans before and after the treatment.
Study NCT03478358 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 177Lu-DOTA-TATE
Description: The patients were intravenously injected with single dose 3.7GBq (100 mCi) of 177Lu-DOTA-TATE and underwent 68Ga-DOTATATE PET/CT scans before and after the treatment.
Study NCT03478358 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 177Lu-DOTA-EB-TATE 2
Description: The patients were intravenously injected with single dose 1.85GBq (50 mCi) of 177Lu-DOTA-EB-TATE and underwent 68Ga-DOTATATE PET/CT scans before and after the treatment.
Study NCT03478358 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 177Lu-DOTA-EB-TATE 3
Description: The patients were intravenously injected with single dose 3.7GBq (100 mCi) of 177Lu-DOTA-EB-TATE and underwent 68Ga-DOTATATE PET/CT scans before and after the treatment.
Study NCT03478358 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3.7 GBq (100 mCi) of 177Lu-DOTA-EB-TATE with amino acids (lysine and arginine)
Description: The patients were intravenously injected with 3.7GBq (100 mCi) of 177Lu-DOTA-EB-TATE and amino acids (lysine and arginine).
Study NCT03478358 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3.7 GBq (100 mCi) of 177Lu-DOTA-EB-TATE without amino acids (lysine and arginine)
Description: The patients were intravenously injected with 3.7GBq (100 mCi) of 177Lu-DOTA-EB-TATE without amino acids (lysine and arginine).
Study NCT03711812 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Serratus Anterior Plane Catheter
Description: Insertion of a Serratus Anterior Plane Catheter to establish a continuous analgesic block with a local anaesthetic infusion
Study NCT04137055 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZSP0678-Dose 3
Description: ZSP0678 tablets administered orally once daily for 14 Days
Study NCT04137055 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZSP0678 Placebo
Description: Participants will receive placebo matching to ZSP0678 orally.
Study NCT00038142 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: 2.0 mg/m\^2 (max 2.0 mg) IV x 1 repeated every 3 weeks X 6.
Study NCT00038142 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vincristine
Description: 2.0 mg/m\^2 (max 2.0 mg) IV x 1 repeated every 3 weeks X 6.
Study NCT00038142 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: 90 mg/m\^2 IV over 30 min x 1 repeated every 3 weeks X 6.
Study NCT00038142 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: 90 mg/m\^2 IV over 30 min x 1 repeated every 3 weeks X 6.
Study NCT00038142 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 2.0 g/m\^2 IV daily x 2 days repeated every 3 weeks X 6.
Study NCT00038142 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: 2.0 g/m\^2 IV daily x 2 days repeated every 3 weeks X 6.
Study NCT00038142 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexrazoxane
Description: 900 mg/m\^2 IV (30 min prior to doxorubicin) repeated every 3 weeks X 6.
Study NCT00038142 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexrazoxane
Description: 900 mg/m\^2 IV (30 min prior to doxorubicin) repeated every 3 weeks X 6.
Study NCT00038142 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ImmTher
Description: 900 mcg/m\^2 IV over 1 hour every week x 50-52 weeks.
Study NCT03137056 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hemodialysis with Theranova
Description: Theranova is a polyarylethersulfone-based hemodialysis membrane manufactured by Baxter International Corp All the dialysis sessions in this arm will be performed with the theranova membrane. This membrane will exclusively be used in hemodialysis.~Modalities of hemodialysis : Blood flow: 300-400 mL/min; Dialysate flow: 500-800 mL/min
Study NCT03137056 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hemodialysis with FX1000
Description: FX1000 is a helixone-based membrane manufactured by Fresenius All the dialysis sessions in this arm will be performed with the FX1000 membrane. This membrane will be used in hemodialysis.~Modalities of hemodialysis: Blood flow: 300-400 mL/min ; Dialysate flow: 500-800 mL/min
Study NCT03137056 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hemodiafiltration with FX1000
Description: FX1000 is a helixone-based membrane manufactured by Fresenius All the dialysis sessions in this arm will be performed with the FX1000 membrane. This membrane will be used in hemodiafiltration Modalities of hemodialysis: Blood flow: 300-400 mL/min; Dialysate flow: 500-800 mL/min ; post reinjection convection volume of at least 25L.
Study NCT04112745 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Static magnet
Description: Static magnet with 2,000 Gauss
Study NCT03612375 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: smoking cessation counseling
Description: Participants in the control group will receive smoking cessation counseling only. Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 24-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6, 12 and 24 months, participants will be asked to come to a clinical visit.
Study NCT01819571 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluid loading (Voluven)
Description: HES 130/0.4 (VoluvenⓇ, Fresenius Kabi, Graz, Austria) 8ml / kg loading during 15 minutes after induction of anesthesia on both groups
Study NCT04112745 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Polyvinyl chloride resin material black jewelry
Study NCT00886691 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given IV
Study NCT00886691 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Given PO
Study NCT00886691 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT00886691 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Given PO
Study NCT03711812 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Thoracic Epidural Catheter
Description: Insertion of a Thoracic Epidural Catheter to establish a continuous analgesic block with a local anaesthetic infusion
Study NCT03722992 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: MBSR
Description: Guided yoga and meditation practices